Truist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $181
Benzinga Newsdesk 19 hours ago
Analyst RatingsNewsPrice TargetHot
Truist Securities analyst Gregory Renza maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $158 to $181.
Truist Securities analyst Gregory Renza maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $158 to $181.